Beatriz E Adrada
Overview
Explore the profile of Beatriz E Adrada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel M, Adrada B, Guirguis M, Whitman G, Moseley T, Rauch G
J Breast Imaging
. 2024 Dec;
7(1):104-118.
PMID: 39692400
Molecular breast imaging (MBI) is a functional imaging modality that utilizes technetium 99m sestamibi radiotracer uptake to evaluate the biology of breast tumors. Molecular breast imaging can be a useful...
2.
Yam C, Patel M, Hill H, Sun R, Bassett Jr R, Kong E, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2823-2834.
PMID: 39356138
Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the...
3.
Mohamed R, Panthi B, Adrada B, Boge M, Candelaria R, Chen H, et al.
Sci Rep
. 2024 Jul;
14(1):16073.
PMID: 38992094
Triple-negative breast cancer (TNBC) is often treated with neoadjuvant systemic therapy (NAST). We investigated if radiomic models based on multiparametric Magnetic Resonance Imaging (MRI) obtained early during NAST predict pathologic...
4.
Garber H, Basu S, Jindal S, He Z, Chu K, Raghavendra A, et al.
Oncotarget
. 2024 Mar;
15:238-247.
PMID: 38502947
A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered...
5.
Basho R, Zhao L, White J, Huo L, Bassett R, Mittendorf E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300124.
PMID: 38484209
Purpose: The PI3K pathway is frequently altered in triple-negative breast cancer (TNBC). Limited cell line and human data suggest that TNBC tumors characterized as mesenchymal (M) and luminal androgen receptor...
6.
Guirguis M, Arribas E, Kapoor M, Patel M, Perez F, Nia E, et al.
Radiographics
. 2024 Mar;
44(4):e230113.
PMID: 38483829
The nipple-areolar complex (NAC), a unique anatomic structure of the breast, encompasses the terminal intramammary ducts and skin appendages. Several benign and malignant diseases can arise within the NAC. As...
7.
Musall B, Rauch D, Mohamed R, Panthi B, Boge M, Candelaria R, et al.
J Magn Reson Imaging
. 2024 Jan;
60(4):1367-1376.
PMID: 38294179
Background: Assessment of treatment response in triple-negative breast cancer (TNBC) may guide individualized care for improved patient outcomes. Diffusion tensor imaging (DTI) measures tissue anisotropy and could be useful for...
8.
Zhou Z, Adrada B, Candelaria R, Elshafeey N, Boge M, Mohamed R, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2023 Dec;
2023:1-4.
PMID: 38083160
We trained and validated a deep learning model that can predict the treatment response to neoadjuvant systemic therapy (NAST) for patients with triple negative breast cancer (TNBC). Dynamic contrast enhanced...
9.
Panthi B, Mohamed R, Adrada B, Boge M, Candelaria R, Chen H, et al.
Front Oncol
. 2023 Nov;
13:1264259.
PMID: 37941561
Early prediction of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) patients could help oncologists select individualized treatment and avoid toxic effects associated with ineffective therapy in patients...
10.
Xu Z, Rauch D, Mohamed R, Pashapoor S, Zhou Z, Panthi B, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835523
Accurate tumor segmentation is required for quantitative image analyses, which are increasingly used for evaluation of tumors. We developed a fully automated and high-performance segmentation model of triple-negative breast cancer...